| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy |
|
Medicine details |
|
| Medicine name | olaparib (Lynparza®) |
| Formulation | 100mg,150mg film-coated tablets |
| Reference number | 34 |
| Indication | Monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2022 |
| NICE guidance | |